• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Off-label use of medication may be presented in these guidelines if a sufficient level of
evidence shows that it can be considered medically appropriate to a given condition and if …

Importance Nonrandomized studies using insurance claims databases can be analyzed to
produce real-world evidence on the effectiveness of medical products. Given the lack of …

Aim The guideline for coronary artery revascularization replaces the 2011 coronary artery
bypass graft surgery and the 2011 and 2015 percutaneous coronary intervention guidelines …

Although substantial progress has been made in the diagnosis and treatment of acute
coronary syndromes, cardiovascular disease remains the leading cause of death globally …

Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …

CYP2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19
genotype impacts clopidogrel active metabolite formation. CYP2C19 intermediate and poor …

2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …

Importance Clopidogrel monotherapy after short dual antiplatelet therapy (DAPT) after
percutaneous coronary intervention (PCI) has not yet been fully investigated in patients with …